J. McCoy

Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib

Fred R. Hirsch, Marileila Varella‐Garcia, Federico Cappuzzo et al. · Annals of Oncology · 2007 · 270 citations · Full text

Medicine, Molecular Genetics, Oncology +16

Gefitinib (ZD1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) Study S0126

Howard West, W. Franklin, Paul H. Gumerlock et al. · Journal of Clinical Oncology · 2004 · 47 citations

Medicine, Oncology, Pharmacology +16

Mutational analysis of <i>K-RAS</i> and <i>EGFR</i> implicates <i>K-RAS</i> as a resistance marker in the Southwest Oncology Group (SWOG) trial S0126 of bronchioalveolar carcinoma (BAC) patients (pts) treated with gefitinib

Paul H. Gumerlock, William Holland, H. Chen et al. · Journal of Clinical Oncology · 2005 · 35 citations

Medicine, Oncology, Pharmacology +17

Predicting clinical benefit from EGFR TKIs: Not all EGFR mutations are equal

F. R. Hirsch, Wilbur A. Franklin, J. McCoy et al. · Journal of Clinical Oncology · 2006 · 25 citations

Medicine, Molecular Genetics, Oncology +14

Bortezomib + gemcitabine (Gem)/carboplatin (Carbo) results in encouraging survival in advanced non-small cell lung cancer (NSCLC): Results of a phase II Southwest Oncology Group (SWOG) trial (S0339)

Angela M. Davies, J. McCoy, Primo N. Lara et al. · Journal of Clinical Oncology · 2006 · 23 citations

Medicine, Oncology, Pharmacology +14